Navigation Links
Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Date:3/25/2009

CRANBURY, N.J., March 25 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the issuance on March 10, 2009 of United States Patent No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of Use." The patent covers the tartrate salt form of isofagomine, the active ingredient in the Company's investigational drug Plicera(TM) (afegostat tartrate), and its use for the treatment of Gaucher disease. The patent will expire in 2027.

John F. Crowley, President and CEO of Amicus, commented, "The issuance of this patent further strengthens our protection in the United States for Plicera in Gaucher and is one example of our ongoing efforts to establish a comprehensive intellectual property portfolio for our development programs and our pharmacological chaperone technology platform."

Plicera is currently being studied in an ongoing Phase 2 study in patients naive to enzyme replacement therapy. This six-month study is designed to evaluate safety and to demonstrate trends of efficacy, as measured by the standard endpoints in Gaucher disease. Amicus previously reported that enrollment has been completed for the study and the Company expects the results to be available in the third quarter of 2009.

Amicus is developing Plicera as part of a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the collaboration, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic d
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Oxis Biotech, Inc. ... International, Inc. [OTC: OXIS] and [Euronext Paris: ... exclusive option agreement with the University of ... by Dr. Xiang-Qun Xie , Associate ... Sciences, School of Pharmacy.  These patents/intellectual properties ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
(Date:3/26/2015)... , March 26, 2015  CNBC profiled MJ Freeway ... part of a series "How I Did It," which features ... the High Road" released yesterday, illustrates how two tech ... leading IT providers to the marijuana industry. ... describes how Co-Founders Amy Poinsett and Jessica Billingsley ...
Breaking Medicine Technology:Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2
(Date:3/26/2015)... 26, 2015 Dr. Alex Rabinovich and ... announce expanded offerings for Bay Area patients considering dental ... Center has long been a top-rated center, serving primarily ... to meet the strong demand by others throughout Northern ... a top-rated dental implant facility in San Francisco,”explained Dr. ...
(Date:3/26/2015)... March 26, 2015 Pacific Medical LLC, ... pleased to be featured on Innovations with Ed Begley ... 18, 2015. The episode will repeat on local ... on the Pacific Medical home page at: http://www.pacificmedicalsupply.com ... emergencies, it is reassuring to trust the integrity of ...
(Date:3/26/2015)... Altamonte Springs, FL (PRWEB) March 26, 2015 ... one of the nation’s leading innovative specialty pharmacies, ... newly created position of Vice President of Pharmaceutical ... for fostering beneficial connections with our pharmaceuticals partners ... pharmaceutical relationships in support of BioPlus’ expansion. ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The ... for Assessment and Evaluation , has announced its ... enable institutions, organizations, and corporations to accurately and ... successful learning. , Utilizing Questionmark’s state-of-the-art software ... will offer improved delivery of the seventy-five ...
(Date:3/26/2015)... In the key developed markets, the hypertension ... is set to decrease through 2020 at a negative CAGR ... expected up to 2017 at a 2.6% CAGR and a ... to the surging penetration of fixed-dose combination drugs like Azor, ... Benicar HCT, and Tekamlo), a hike in the prevalence population ...
Breaking Medicine News(10 mins):Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:NLN Testing Services Announces Improved Delivery and Analytics Software and Newly Developed and Revised Exams 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3
... repeat problems seen in 1976 episode , TUESDAY, July ... in 1976 to vaccinate 43 million people against swine ... the dreaded outbreak never materialize (illness never spread beyond ... 500 Americans who did get vaccinated came down with ...
... , Innovative child welfare practices from across ... , , SEATTLE, July 21 ... way they do business. These changes are improving the lives of children ... care. , , (Logo: ...
... AlphaRx plans to open an R&D facility and manufacturing plant ... innovative drug products to the fastest, growing ... July 21 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an ... novel formulations of drugs, is forging ahead with its growth ...
... , , Clinical ... inspections , , Washington, ... the same safety, ethical and quality standards as those conducted in ... report released today by the Association of Clinical Research Organizations (ACRO). ...
... , , BALTIMORE, July 21 ... to people that want to take control of their health, and ... to employers announced that they have reached an agreement to bring ... their employees - "stay healthy." , , ...
... , SCOTTSDALE, Ariz., July 21 ... in their personal expenses. No longer are trendy fashion statements considered ... into aesthetic treatments aimed at improving or enhancing appearance, and those ... , Suggestions to make the most of your beauty ...
Cached Medicine News:Health News:Safety of Swine Flu Vaccine to Face Tough Scrutiny 2Health News:Safety of Swine Flu Vaccine to Face Tough Scrutiny 3Health News:Safety of Swine Flu Vaccine to Face Tough Scrutiny 4Health News:New Report Sets a Course for Improving Foster Care Systems 2Health News:New Report Sets a Course for Improving Foster Care Systems 3Health News:AlphaRx Unveils its China Strategy 2Health News:Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says 2Health News:Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says 3Health News:Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says 4Health News:Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says 5Health News:Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 2Health News:Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 3Health News:The Secrets to Staying Beautiful; Making the Most of Your Beauty Budget 2Health News:The Secrets to Staying Beautiful; Making the Most of Your Beauty Budget 3
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Sodium in serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: